Skip to main content

"Forget software, the real opportunity is in exporting healthcare"

Are Indian companies going to be able to provide enough jobs for the increasing millions of young Indians that are going to graduate each year? If not, the oft spoken about "demographic dividend" is likely to turn out to be more of a "demographic curse".

In this context, Businessworld has an interesting article pointing out that the big opportunity in exporting healthcare workers from India to more advanced whose populations are ageing fast healthcare costs are zooming.
As critics of the demographic dividend thesis point out, the focus is all on the supply of labour, while very little is said about demand. Admittedly, the additional supply of labour does offer the potential for employment and growth. But there is no guarantee that demand would match supply and lead to more jobs and production. The fact is, India will have to provide employment for 15 million job entrants every year and not 10 million as estimated earlier. “We haven’t done even 10 million yet,” points out Debroy. One concern here is that nearly half of India reports itself as self-employed and this is not just in agriculture. “Therefore, we shouldn’t think in terms of employer-employee relationships alone; we need to look at skills, access to credit, land markets, healthcare, physical connectivity (roads, power).”

On the other side are experts who believe that the demographically dying countries of Europe (Germany, Italy, Russia) offer India a great opportunity to export labour. The ageing population of Europe means there will be tremendous demand for healthcare workers, from doctors, nurses and attendants. In 20 years, the world will be swamped by people of over 80 years, and this will be a huge chance for Indians if we provide them with the proper skills, says eminent demographer Ashish Bose, honorary professor, Institute of Economic Growth, Delhi, and member of the National Commission on Population.

...Bose, who leads the optimists brigade, says we need a more energetic policy to tap the potential. “Forget software,” he says. “Train our young people in healthcare. Give them a crash course in languages. The next quarter century is ours because India is a demographic giant.”

Elsewhere in the same issue of Businessworld, a column titled "Better Red Than Dead" by Kenneth Rogoff, a Harvard Professor of Economics and Public Policy and former IMF chief economist, shows how desperately the West needs to lower healthcare costs. He forecasts that the inexorable rise in medical costs will in the near future test the "moral, social and political support for capitalism".
Rising incomes, population ageing and new technologies for enhancing life have caused health costs to rise 3.5 per cent faster than overall income for many decades now in the US. Some leading economists project that health expenditures, which now constitute 16 per cent of the US economy, will rise to 30 per cent of GDP by 2030, and perhaps approach 50 per cent later in the century. Countries in Europe and elsewhere have shielded their citizens from a part of this rise by piggybacking on US technological advances. Ultimately, though, they face the same upward cost pressures.

...Many societies view healthcare as a right, not a luxury. When medical expenses constituted only a small percentage of income, as was typically the case 50 years ago, an egalitarian approach to healthcare was a small extravagance. The direct and indirect costs were relatively minor and affordable.

But as health expenses start taking up a third of national income, healthcare socialism starts becoming just plain Marxism: to each according to his needs. Even China’s authoritarion capitalism will someday feel the pressure, as its rural populations, who currently have little access to doctors or hospitals, eventually explode with discontent.




Arun Natarajan is the Founder & CEO of Venture Intelligence, the leading provider of information and networking services to the private equity and venture capital ecosystem in India. View free samples of Venture Intelligence newsletters and reports.

Popular posts from this blog

EY Tops League Table for Transaction Advisors to M&A deals in 24

Moelis & Company & PwC claim the No.2 & No.3 slots Ernst & Young  (EY) topped the Venture Intelligence League Table for Transaction Advisor to M&A Deals   during 2024, advising 34 deals worth $4.1 Billion. Moelis & Company stood second advising 2 deals worth $3.9 billion. PwC followed with 18 deals worth $3.3 billion. Citi ($2.5 billion across 1 deal) and Advay Capital ($2.3 billion across 1 deal) completed the top five. Among the largest M&A deals in 2024, Citi  advised $2.5 Billion acquisition of the Indian business of American Tower Corporation by Brookfield , Advay Capital and Moelis & Company advised the $2.3 Billion acquisition of Care Hospitals by Aster DM Healthcare . Jefferies & Co., JP Morgan and Moelis & Company advised the $1.6 Billion acquisition of Bharat Serums & Vaccines by Mankind Pharma.  Among the other notable M&A deals in Q4 2024, EY advised the $685 million acquisition of ITD Cementation ...

Morgan Stanley tops League Table for Transaction Advisors to M&A deals in 2020

Morgan Stanley , which advised the $10.1 Billion strategic investment by Facebook and Google into Reliance Industries' telecom arm Jio platforms (among other Private Equity investments in the company), topped the Venture Intelligence League Table for Transaction Advisor to M&A Deals for 2020. Ambit Corporate Finance - which advised 3 deals worth $4.0 Billion, including Brookfield's $3.7 Billion acquisition of Reliance Tower Infrastructure Trust -  took the second spot. JM Financial ($3.7 Billion across 5 deals), Metta Capital ($3.4 Billion across 3 deals) and ICICI Securities ($3.4 Billion across 2 deals) - all of whom (along with Citi) are advisors to the $3.4 Billion acquisition of Future Group's retail related ventures by Reliance Retail, announced in August - completed the top five. The  Venture Intelligence League Tables , the first such initiative exclusively tracking transactions involving India-based companies, are based on the value of PE and M&A tra...

Everything you wanted to know (and some things you didn't care to know) about ChrysCapital's Ashish Dhawan

New Delhi-based private equity fund ChrysCapital is vastly different from its former avatar, Chrysalis Capital. While Chrysalis began life (in Mumbai) as an venture capital firm focussed on start-up investments, today's ChrysCapital is best know for its late-stage investments (often in already public companies). The fascinating part of this transformation is that one of the fund's original partners - Senior Managing Director Ashish Dhawan - has been firmly in the driver's seat throughout the process. It's a story that needed to be told. As a cover story. Kudos to Business Today for telling it first. Thankfully, unlike the glowing profiles that BT is famous for - including the one featuring infamous stock brocker Harshad Mehta with his Lexus on the cover - this one has a lot of facts. Some well known. And others less so. That ChrysCapital's first fund would have been a disaster but for the pioneering investment in Raman Roy founded BPO firm Spectramind i...

Why did Sony Entertainment Television's CEO quit?

Businessworld has a cover story on the corporate battle that resulted in Kunal Dasgupta, the CEO of Multi Screen Media (formerly Sony Entertainment Television), quitting just a few months before his contract was due to end. Dasgupta’s abrupt exit was the culmination of six years of tension between majority shareholder Sony Pictures Television International (SPTI) that owns 61 per cent of MSM, on one hand, and Atlas Equifinn on the other, which is a consortium of Indian shareholders (Singapore-based Rakesh Aggarwal, World Media Group director Sudesh Iyer, Shemaroo Entertainment Managing Director Raman Maroo, MobiApps Holding’s Jayesh Parekh, B.R. Sule, Sushil Shergil and actor Jackie Shroff ) holding 32 per cent. Capital Japan and some financial institutions own the rest 7 per cent. And of course, the third protagonist is Dasgupta, who walked a tightrope and managed to keep his job for over 14 years despite the fact that neither group of shareholders was too happy with him. Very little...

APEX VC Awards: Chiratae Ventures, Blume Ventures, Elevation Capital, Stride Ventures & Alteria Capital judged best funds of 2021

Press Release Elevation Capital , Chiratae Ventures , Blume Ventures , Stride Ventures and Alteria Capital were voted the top Venture Capital investors in India during 2021. The Venture Intelligence “Awards for Private Equity Excellence” (APEX) is dedicated to celebrating the best that the Indian Private Equity & Venture Capital industry has to offer. "VCs exist because Entrepreneurs exist and disrupt the ecosystem by creating new businesses. We are very excited to be part of the secular trend of tech disruption that would power India’s journey towards $ 10 Trillion economy over the next decade," said  T C Meenakshi Sundaram, Founder & Vice Chairman, Chiratae Ventures , winner of " VC Fund raise of the Year " award.  " We wish to thank all our entrepreneurs who have chosen to take funding from Chiratae Ventures and investors who have backed us with funds over the past 15 years in this journey.  Congratulations to the entire Chiratae Ventures team and ...